Exercise in Men With Prostate Cancer

A Pilot Study of Exercise in Men With Prostate Cancer Receiving Androgen Depletion Therapy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00834392

Enrollment

Registered

2009-02-03

Start date

2008-10-31

Completion date

2010-12-31

Last updated

2011-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Brief summary

The purpose of this pilot study is to compare a walking exercise program (Exercise Group) to standard medical care (Control Group) in prostate cancer survivors receiving androgen depletion therapy (ADT). The central hypothesis of the proposed research is that the walking exercise program will have a positive impact on the bone health, health-related quality of life, and physical function of men with prostate cancer receiving ADT.

Interventions

BEHAVIORALExercise

Walking exercise

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

MALE

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* men aged 50 years or older * diagnosed with adenocarcinoma prostate cancer * will initiate and receive continuous ADT (luteinizing hormone releasing hormone agonist (LHRH) or combination of LHRH and anti-androgen) for at least 12 months after recruitment * Patients will also consent to participating in the study.

Exclusion criteria

* severe cardiac disease (New York Heart Association class III or greater) * angina * severe osteoporosis * uncontrolled hypertension (blood pressure \> 160/95mm Hg) * orthostatic blood pressure drop \> 20mm Hg * moderate to severe aortic stenosis * acute illness or fever * uncontrolled atrial or ventricular dysrhythmias * uncontrolled sinus tachycardia (\> 120 beats per minute) * uncontrolled congestive heart failure third-degree atrio-ventricular heart block, active pericarditis or myocarditis, recent embolism, thrombophlebitis, deep vein thrombosis, resting ST displacement (\> 3mm), uncontrolled diabetes, uncontrolled pain, cognitive impairment, history of falls due to balance impairment or lost of consciousness, severe neuromusculoskeletal conditions that limit their ability to perform walking exercise (including ataxia, peripheral or sensory neuropathy, unstable bone lesion, severe arthritis, pathological lower limb fractures within 6 months, lower limb amputation).

Design outcomes

Primary

Measure	Time frame
bone health	baseline, 12 months

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026